用于多发性骨髓瘤临床试验的树突状细胞。

Dendritic cells in clinical trials for multiple myeloma.

作者信息

Reichardt Volker L, Brossart Peter

机构信息

Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.

出版信息

Methods Mol Med. 2005;109:127-36. doi: 10.1385/1-59259-862-5:127.

DOI:10.1385/1-59259-862-5:127

PMID:15585918

Abstract

Due to the existence of the truly specific tumor antigen idiotype in multiple myeloma and based on encouraging data from dendritic cell vaccinated B-cell non-Hodgkin's lymphoma (NHL) patients, dendritic cell-based vaccination was first initiated in myeloma patients in 1995. This overview will summarize published and ongoing clinical trials in patients with multiple myeloma who are treated with idiotype-based dendritic cell (Id/DC) vaccination. All groups of investigators have found that Id/DC vaccination of multiple-myeloma patients is feasible and that myeloma-specific immunity can be induced in heavily pretreated individuals. In future trials, new dendritic cell-based immunization strategies will be investigated based on techniques like RNA transfection of DC.

摘要

由于多发性骨髓瘤中存在真正特异性的肿瘤抗原独特型，并且基于树突状细胞疫苗接种的B细胞非霍奇金淋巴瘤（NHL）患者的鼓舞人心的数据，基于树突状细胞的疫苗接种于1995年首次在骨髓瘤患者中开展。本综述将总结已发表的以及正在进行的、针对接受独特型树突状细胞（Id/DC）疫苗接种治疗的多发性骨髓瘤患者的临床试验。所有研究团队均发现，对多发性骨髓瘤患者进行Id/DC疫苗接种是可行的，并且在经过大量预处理的个体中可诱导产生骨髓瘤特异性免疫。在未来的试验中，将基于如树突状细胞的RNA转染等技术研究新的基于树突状细胞的免疫策略。